You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新開源(300109.SZ):與Abcam籤戰略合作協議 做大做強體外診斷領域
格隆匯 10-28 08:34

格隆匯10月28日丨新開源(300109.SZ)公佈,公司與Abcam Plc(簡稱“Abcam”)於2021年10月27日正式簽署戰略合作協議。Abcam總部位於英國劍橋,成立於1998年,為全球130多個國家約75萬名生命科學研究人員和臨牀團體提供經過高度驗證的抗體、試劑、生物標記物、檢測方法和其他科學研究工具;其為納斯達克、倫交所AIM市場上市公司。

在簽署協議後的五年期限內,Abcam將向新開源提供其目錄中的親和試劑以及定製服務,供新開源在體外診斷(IVD)領域的產品開發和商業化中使用。Abcam將向新開源及其關聯公司授予目錄親和試劑的非獨家許可和定製親和試劑的獨家許可,供新開源用於IVD應用、第三方機構的研發活動和新開源所開發產品的銷售。

新開源應有權從Abcam購買定製和目錄親和試劑,並使用Abcam的親和試劑開發經批准的臨牀產品。如果新開源使用Abcam的目錄產品開發出一個或多個經批准的臨牀產品,新開源需向Abcam支付里程碑費用和銷售佣金。

公司表示,該協議的正式簽署,符合公司“消費類特種化學品平台+健康醫療服務平台”雙平台的長期發展戰略。通過雙方建立的戰略合作,Abcam將助力公司在體外診斷領域擁有更為全面的產品組合和服務,公司也可以藉助Abcam的品牌影響力和全球市場渠道,在體外診斷領域進一步做大做強。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account